Primary Occurrence of Cardiovascular Events After Adding Sodium-Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American College of Physicians--American Society of Internal Medicine Country of Publication: United States NLM ID: 0372351 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1539-3704 (Electronic) Linking ISSN: 00034819 NLM ISO Abbreviation: Ann Intern Med Subsets: MEDLINE
    • Publication Information:
      Publication: <2001->: Philadelphia, PA : American College of Physicians--American Society of Internal Medicine
      Original Publication: Philadelphia [etc.] American College of Physicians.
    • Subject Terms:
      Dipeptidyl-Peptidase IV Inhibitors*/adverse effects ; Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/drug therapy ; Diabetes Mellitus, Type 2*/epidemiology ; Cardiovascular Diseases*/epidemiology ; Cardiovascular Diseases*/prevention & control ; Cardiovascular Diseases*/etiology ; Veterans* ; Sodium-Glucose Transporter 2 Inhibitors*/adverse effects ; Heart Failure*/epidemiology ; Heart Failure*/prevention & control ; Heart Failure*/chemically induced; Humans ; Aged ; United States/epidemiology ; Hypoglycemic Agents/adverse effects ; Cohort Studies ; Glucagon-Like Peptide-1 Receptor/agonists ; Retrospective Studies ; Treatment Outcome ; Medicare ; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use ; Glucose/therapeutic use ; Sodium/therapeutic use
    • Abstract:
      Background: The effectiveness of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in preventing major adverse cardiac events (MACE) is uncertain for those without preexisting cardiovascular disease.
      Objective: To test the hypothesis that MACE incidence was lower with the addition of GLP1RA or SGLT2i compared with dipeptidyl peptidase-4 inhibitors (DPP4i) for primary cardiovascular prevention.
      Design: Retrospective cohort study of U.S. veterans from 2001 to 2019.
      Setting: Veterans aged 18 years or older receiving care from the Veterans Health Administration, with data linkage to Medicare, Medicaid, and the National Death Index.
      Patients: Veterans adding GLP1RA, SGLT2i, or DPP4i onto metformin, sulfonylurea, or insulin treatment alone or in combination. Episodes were stratified by history of cardiovascular disease.
      Measurements: Study outcomes were MACE (acute myocardial infarction, stroke, or cardiovascular death) and heart failure (HF) hospitalization. Cox models compared the outcome between medication groups using pairwise comparisons in a weighted cohort adjusted for covariates.
      Results: The cohort included 28 759 GLP1RA versus 28 628 DPP4i weighted pairs and 21 200 SGLT2i versus 21 170 DPP4i weighted pairs. Median age was 67 years, and diabetes duration was 8.5 years. Glucagon-like peptide-1 receptor agonists were associated with lower MACE and HF versus DPP4i (adjusted hazard ratio [aHR], 0.82 [95% CI, 0.72 to 0.94]), yielding an adjusted risk difference (aRD) of 3.2 events (CI, 1.1 to 5.0) per 1000 person-years. Sodium-glucose cotransporter-2 inhibitors were not associated with MACE and HF (aHR, 0.91 [CI, 0.78 to 1.08]; aRD, 1.28 [-1.12 to 3.32]) compared with DPP4i.
      Limitation: Residual confounding; use of DPP4i, GLP1RA, and SGLT2i as first-line therapies were not examined.
      Conclusion: The addition of GLP1RA was associated with primary reductions of MACE and HF hospitalization compared with DPP4i use; SGLT2i addition was not associated with primary MACE prevention.
      Primary Funding Source: VA Clinical Science Research and Development and supported in part by the Centers for Diabetes Translation Research.
      Competing Interests: Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-2751.
    • References:
      Lancet. 2019 Jan 5;393(10166):31-39. (PMID: 30424892)
      JAMA. 2018 Apr 17;319(15):1580-1591. (PMID: 29677303)
      Rev Endocr Metab Disord. 2021 Dec;22(4):1171-1188. (PMID: 34228302)
      BMC Cardiovasc Disord. 2017 Jun 12;17(1):151. (PMID: 28606104)
      Circulation. 2022 Mar;145(9):e722-e759. (PMID: 35000404)
      BMJ. 2018 Sep 4;362:k1497. (PMID: 30181166)
      Cardiovasc Diabetol. 2018 Dec 13;17(1):157. (PMID: 30545359)
      Lancet. 2019 Jul 13;394(10193):121-130. (PMID: 31189511)
      JAMA. 2019 Sep 24;322(12):1155-1166. (PMID: 31536101)
      N Engl J Med. 2015 Jul 16;373(3):232-42. (PMID: 26052984)
      Am Heart J. 2011 Sep;162(3):548-54. (PMID: 21884875)
      Ann Intern Med. 2022 Jul;175(7):927-937. (PMID: 35605236)
      PLoS One. 2020 Mar 4;15(3):e0229621. (PMID: 32130249)
      Int J Hypertens. 2013;2013:653789. (PMID: 23533715)
      Circulation. 1999 Sep 7;100(10):1134-46. (PMID: 10477542)
      Diabetes Care. 2021 May;44(5):1159-1167. (PMID: 33653824)
      N Engl J Med. 2013 Oct 3;369(14):1327-35. (PMID: 23992602)
      N Engl J Med. 2019 Jan 24;380(4):347-357. (PMID: 30415602)
      N Engl J Med. 2016 Mar 24;374(12):1145-54. (PMID: 27007958)
      Circulation. 2019 Apr 23;139(17):2022-2031. (PMID: 30786725)
      JAMA Cardiol. 2021 May 1;6(5):499-507. (PMID: 33595593)
      Arch Gen Psychiatry. 2001 Dec;58(12):1161-7. (PMID: 11735845)
      BMJ Open. 2018 Mar 25;8(3):e020455. (PMID: 29581206)
      Circ Heart Fail. 2018 Mar;11(3):e004457. (PMID: 29664406)
      JACC Basic Transl Sci. 2020 Jun 22;5(6):632-644. (PMID: 32613148)
      N Engl J Med. 2016 Nov 10;375(19):1834-1844. (PMID: 27633186)
      JAMA Cardiol. 2021 Feb 1;6(2):148-158. (PMID: 33031522)
      N Engl J Med. 2017 Aug 17;377(7):644-657. (PMID: 28605608)
      N Engl J Med. 2013 Oct 3;369(14):1317-26. (PMID: 23992601)
      Int J Biostat. 2013 Jul 31;9(2):215-34. (PMID: 23902694)
      Ann Intern Med. 2021 Nov;174(11):1528-1541. (PMID: 34570599)
      N Engl J Med. 2019 Jun 13;380(24):2295-2306. (PMID: 30990260)
      N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
      Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:129-40. (PMID: 22262599)
      Cardiovasc Diabetol. 2020 Jul 6;19(1):107. (PMID: 32631337)
      JAMA. 2019 Jan 1;321(1):69-79. (PMID: 30418475)
      Epidemiology. 2013 Mar;24(2):334-5. (PMID: 23377095)
      Stat Med. 2017 May 30;36(12):1946-1963. (PMID: 28208229)
      Ann Intern Med. 2009 May 5;150(9):604-12. (PMID: 19414839)
      Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. (PMID: 34964831)
      N Engl J Med. 2022 Sep 22;387(12):1075-1088. (PMID: 36129997)
      Ann Intern Med. 2017 Aug 15;167(4):268-274. (PMID: 28693043)
      Front Endocrinol (Lausanne). 2021 Aug 23;12:721135. (PMID: 34497589)
      N Engl J Med. 2020 Oct 8;383(15):1425-1435. (PMID: 32966714)
      N Engl J Med. 2016 Jul 28;375(4):311-22. (PMID: 27295427)
      Circulation. 2019 Jan 15;139(3):351-361. (PMID: 30586723)
      Trends Endocrinol Metab. 2018 Apr;29(4):238-248. (PMID: 29463450)
      Ann Intern Med. 2016 Jun 7;164(11):705-14. (PMID: 27110660)
      Diabetes Obes Metab. 2020 Feb;22(2):167-172. (PMID: 31486269)
      Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. (PMID: 34425083)
      Lancet. 2010 Nov 13;376(9753):1670-81. (PMID: 21067804)
      N Engl J Med. 2015 Nov 26;373(22):2103-16. (PMID: 26551272)
    • Grant Information:
      I01 CX000570 United States CX CSRD VA; P30 DK092986 United States DK NIDDK NIH HHS; SDR 02-237 United States HX HSRD VA
    • Accession Number:
      0 (Dipeptidyl-Peptidase IV Inhibitors)
      0 (Hypoglycemic Agents)
      0 (Glucagon-Like Peptide-1 Receptor)
      0 (Sodium-Glucose Transporter 2 Inhibitors)
      EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
      IY9XDZ35W2 (Glucose)
      9NEZ333N27 (Sodium)
    • Publication Date:
      Date Created: 20230508 Date Completed: 20230621 Latest Revision: 20231202
    • Publication Date:
      20240628
    • Accession Number:
      PMC10367222
    • Accession Number:
      10.7326/M22-2751
    • Accession Number:
      37155984